Full Press Release Details
Neuralstem, Inc. Announces Approval for
Listing on the NASDAQ Capital Market
GERMANTOWN, MD, June 29, 2015 -- Neuralstem,
Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy
treatments for central nervous system diseases, announced today that it has been approved for listing on the NASDAQ Capital Market
under the symbol "CUR." The Company's common stock will continue to trade on the NYSE MKT until the market close
on July 10, 2015. Trading on the NASDAQ Capital Market is expected to commence on July 13, 2015.
Neuralstem's patented technology enables
the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the potential
treatment of central nervous system diseases and conditions.
Neuralstem's ability to generate
human neural stem cell lines for chemical screening has led to the discovery and patenting of compounds that Neuralstem believes
may stimulate the brain's capacity to generate neurons, potentially reversing pathologies associated with certain central nervous
system (CNS) conditions. The company has completed Phase Ia and Ib trials evaluating NSI-189, its first neurogenic small molecule
product candidate, for the treatment of major depressive disorder (MDD), and is expecting to initiate a Phase II study for MDD
and a Phase Ib study for cognitive deficit in schizophrenia in 2015.
Neuralstem's first stem cell product
candidate, NSI-566, a spinal cord-derived neural stem cell line, is under development for treatment of amyotrophic lateral sclerosis
(ALS). Neuralstem has completed two clinical studies, in a total of thirty patients, that met primary safety endpoints. In addition
to ALS, NSI-566 is also in a Phase I trial in chronic spinal cord injury at UC San Diego School of Medicine, as well as in clinical
development to treat ischemic stroke.
Neuralstem's next generation stem
cell product, NSI-532.IGF, consists of human cortex-derived neural stem cells that have been engineered to secrete human insulin-like
growth factor 1 (IGF-1). In animal data presented at the Congress of Neurological Surgeons 2014 Annual Meeting, the cells rescued
spatial learning and memory deficits in an animal model of Alzheimer's disease.
For more information, please
visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn
Cautionary Statement Regarding Forward Looking Information:
This news release contains "forward-looking
statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements relate to future, not past, events and may often be identified by words such as "expect,"
"anticipate," "intend," "plan," "believe," "seek" or "will."
Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties
that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent
in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual
results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential
factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic
reports, including the Annual Report on Form 10-K for the year ended December 31, 2014, Form 10-Q for the period ended March 31,
2015, and in other reports filed with the SEC.
Neuralstem - Investor Relations:
Danielle Spangler 301.366.1481
Planet Communications - Media Relations:
Deanne Eagle 917.837.5866
MDC Group - Investor Relations:
Susan Roush 747.222.7012
David Castaneda 414.351.9758